

*The proposal of the nomination committee:* **Christine Roth** to be elected as a new Board member for a term that ends at the end of the next AGM.



**Christine Roth.** Ms. Roth currently serves as Executive Vice President, Head of the Oncology Strategic Business Unit and Member, Pharmaceuticals Executive Committee at Bayer Pharmaceuticals. Her responsibilities include global product strategy, clinical development, clinical operations, regulatory, medical affairs, and market access. Concurrently, she is Senior Vice President, Global Oncology Therapy Area Head, at GlaxoSmithKline (GSK). Prior to these roles, she served as Vice President, US Breast Cancer Franchise Head and Vice President, Global Disease Leader, Hematology at Novartis. Her extensive experiences in the pharma space includes roles at GSK, as both the Global and US Commercialization Lead, and numerous executive and leadership roles at Bristol Myers Squibb. Ms. Roth has a Bachelor's degree in Chemistry and has attained a Wharton Executive Education.

